PRA HEALTH SCIENCES UNVEILS INNOVATIVE TOKENISATION SOLUTION USING SYNOMA®

KUALA LUMPUR, May 17 (Bernama) -- PRA Health Sciences Inc has announced an innovative tokenisation solution using Synoma®, PRA’s proprietary technology, allowing for the generation of enhanced evidence for drug development.

PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront.

To date, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, use Synoma to link data and conduct analyses across their drug development portfolios, according to a statement.

“Data of all types is widely available from dozens of sources. The missing link, however, is the ability to connect clinical trial data to the insights from real-world data – enabling researchers to understand what is happening outside and after a study in a way that protects privacy,” said PRA Health Sciences Executive Vice President and Chief Scientific Officer, Kent Thoelke.

“Tokenisation and linking is the approach researchers can use to glean the greatest insights into drug safety and effectiveness over time.”

Meanwhile, PRA Health Sciences Senior Vice President, Digital Health, Jane Quigley said: “Through our acquisition of Symphony Health and partnership with other data sources, we have enabled scientists and research teams to more intelligently evaluate a wider set of data to inform clinical trial protocols, leverage real-world data as eSource, conduct advanced feasibility, speed enrollment and, ultimately, bring novel and differentiated therapies to market faster.”

PRA can partner with a variety of tokens to multiple sources of information – making it possible to incorporate broader sets of real-world data and revolutionise evidence generation and insights as envisioned by the 21st Century Cures Act.

More details at www.prahs.com.

-- BERNAMA